BLA 017837 · Iso Tex
Megatope
Albumin Iodinated I-131 Serum · Injection
Last checked: Nov 20, 2026Latest source record: Aug 25, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1976
Feb 23, 1976
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1
0 Phase 3, 0 recruiting
FAERS reports
2
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 1, 2023.
INDICATIONS AND USAGE MEGATOPE is indicated in adults for use in determinations of total blood and plasma volumes.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 23, 1976 Original approval · Type 5 - New Formulation or New Manufacturer
5 products under this application
- MEGATOPE · ALBUMIN IODINATED I-131 SERUM 20uCi/AMP · INJECTABLE, INJECTION · Discontinued
- MEGATOPE · ALBUMIN IODINATED I-131 SERUM 2mCi/VIAL · INJECTABLE, INJECTION · Discontinued
- MEGATOPE · ALBUMIN IODINATED I-131 SERUM 0.5mCi/VIAL · INJECTABLE, INJECTION · Prescription
- MEGATOPE · ALBUMIN IODINATED I-131 SERUM 5uCi/AMP · INJECTABLE, INJECTION · Discontinued
- MEGATOPE · ALBUMIN IODINATED I-131 SERUM 1mCi/VIAL · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Albumin Iodinated I-131 Serum" as an intervention, any sponsor and status, largest first.
- Autoimmune Basis for Postural Tachycardia SyndromeActive, not recruiting
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02725060 · 58 participants (planned) · Start Feb 2016 · Primary completion Feb 2027
Drug: phenylephrine; isoproterenol · For: Postural Orthostatic Tachycardia Syndrome; Postural Tachycardia Syndrome; Tachycardia and 5 more
Sites: Oklahoma City, Oklahoma; Nashville, Tennessee
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1
- headache1
- inappropriate schedule of product administration1
- lacrimation increased1
- nausea1
- product dose omission issue1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
Recalls
2 FDA enforcement reports for this application.
Apr 15, 2019 · Class II · Terminated
Lack of Assurance of Sterility: environmental monitoring report exceeds limits, therefore sterility cannot be assured.
Mar 11, 2019 · Class II · Terminated
Lack of Assurance of Sterility: preliminary environmental monitoring report exceeds limits, therefore sterility cannot be assured.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Iso Tex
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.